Transgenomic, Inc. Announces Appointment of New Board Members

OMAHA, Neb., May 22 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC Bulletin
Board: TBIO) announces that it has appointed Antonius P. Schuh, Ph.D. and
Michael B. McNulty to its Board of Directors.

Dr. Schuh is the Founding Chairman and Chief Executive Officer of Sorrento
Therapeutics, Inc. (STI). STI is a seed-stage biotechnology company built on
a proprietary antibody library construction technology, the STI technology,
which applies RNA transcription rather than PCR for the amplification of
variable lgG domains to yield high fidelity mAb libraries. Prior to STI, Dr.
Schuh was the Founding Chief Executive Officer and Director of AviaraDx, Inc.
AviaraDx was a molecular diagnostics laboratory company focused on oncology
testing which was acquired by bioMerieux. Before leading AviaraDx, Dr. Schuh
was Chief Executive Officer of Arcturus Bioscience, Inc. and Sequenom, Inc.

Mr. McNulty is currently General Manager of Diagnostics at Agilent
Technologies, Inc. Agilent Technologies Inc. is the world's premier
measurement company and a technology leader in communications, electronics,
life sciences and chemical analysis. Prior to his current position he was Vice
President of Laboratory Operations and Chief Compliance Officer of Berkeley
Heartlabs, Inc. Mr. McNulty has previously served as a board member for
Employee Health Programs, Bethesda, MD; Drug Free workplace, plc, London, UK;
ThauMDx LLC, Santa Barbara, CA; and International Cancer Screening
Laboratories, Inc. Mr. McNulty previously ran SmithKline Beecham's Chicago
based reference laboratory prior to the company's transition to become Quest
Diagnostics.

In making this announcement, Transgenomic President and CEO, Craig Tuttle,
stated, "We are very excited to have Dr. Schuh and Mr. McNulty join the
Company's Board of Directors. Combined, they have considerable experience in
molecular diagnostics and, equally important, success in leading and running
diagnostic reference laboratories. With our continued focus on growing
Transgenomic's molecular diagnostic laboratory and pharmacogenomic services
lab, plus focusing our WAVE system and related mutation detection technology
for greater diagnostic and clinical value, their participation on our board
will provide a vital increase in laboratory experience and guidance."

About Transgenomic
Transgenomic is a global biotechnology company that provides unique products
and services for automated high sensitivity genetic variation and mutation
analysis. Their offerings include systems, products, discovery and laboratory
testing services to the academic and medical research, clinical laboratory and
pharmaceutical markets in the fields of Pharmacogenomics and personalized
medicine. Specific offerings include WAVE(R) DHPLC Systems, related
consumables and assay kits, Cytogenetics automated systems, and Transgenomic
Pharmacogenomics and Reference Laboratory Services. Transgenomic
Pharmacogenomics and Laboratory Services utilize their technology and
expertise to provide a menu of mutation scanning tests for over 700
cancer-associated genes and more than 60 validated diagnostic tests to meet
the needs of pharmaceutical and biotech companies, research and clinical
laboratories, physicians and patients. For more information about the
innovative systems, products and services offered by Transgenomic, please
visit: www.transgenomic.com.

Cautionary Statements
Certain statements in this press release constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995, which involve known and unknown risks, uncertainties and other
factors that may cause actual results to be materially different from any
future results, performance or achievements expressed or implied by such
statements. Forward-looking statements include, but are not limited to, those
with respect to management's current views and estimates of future economic
circumstances, industry conditions, company performance and financial results,
including the ability of the Company to grow its involvement in the diagnostic
products and services markets. The known risks, uncertainties and other
factors affecting these forward-looking statements are described from time to
time in reports to the Securities and Exchange Commission. Any change in such
factors, risks and uncertainties may cause the actual results, events and
performance to differ materially from those referred to in such statements.
Accordingly, the company claims the protection of the safe harbor for
forward-looking statements contained in the Private Securities Litigation
Reform Act of 1995 with respect to all statements contained in this press
release.

SOURCE Transgenomic, Inc.

Debra Schneider, Chief Financial Officer of Transgenomic, Inc.,
+1-402-452-5400, investorrelations@transgenomic.com